Glioblastoma

An unsupervised, automated machine learning algorithm successfully identified glioblastoma tumor cells and stratified survival outcomes, according to study results published in eLife.

The FDA recently granted fast track designation to enzastaurin for the treatment of newly diagnosed glioblastoma. It was the top story in hematology/oncology last week.

Today is Glioblastoma Awareness Day.

The FDA granted fast track designation to enzastaurin for the treatment of patients with newly diagnosed glioblastoma, according to a press release from the agent’s manufacturer.

The FDA granted fast track designation to TVI-Brain-1, an adoptive T cell therapy for the treatment of glioblastoma multiforme, according to the agent’s manufacturer.

Phase 1, open-label, interventional trial of drug-resistant immunotherapy with activated, gene-modified gamma-delta T cells in patients with newly diagnosed glioblastoma multiforme receiving maintenance temozolomide chemotherapy

Chimeric antigen receptor T-cell therapies have demonstrated limited antitumor activity in glioblastoma. Although the therapies have been tolerable, response rates have been low and responses lack durability.

Phase 1, open label, dose-escalation trial to determine the maximum tolerated dose of a novel, tumor-specific treatment with autologous EGFRvIII-CARs.

Risk for suicide appeared higher among individuals within the first year of a brain cancer diagnosis compared with the general population, according to a research letter published in JAMA Network Open.

National Brain Tumor Awareness Month is commemorated in May.